当前位置: X-MOL 学术Curr. Alzheimer Res. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Proton Pump Inhibitors and Cognitive Health: Review on Unraveling the Dementia Connection and Co-morbid Risks
Current Alzheimer Research ( IF 2.1 ) Pub Date : 2024-02-28 , DOI: 10.2174/0115672050289946240223050737
Zuber Khan 1 , Sidharth Mehan 1 , Mohd. Anas Saifi 2 , Ghanshyam Das Gupta 3 , Acharan S. Narula 4 , Reni Kalfin 5, 6
Affiliation  

Dementia, an international health issue distinguished by the impairment of daily functioning due to cognitive decline, currently affects more than 55 million people worldwide, with the majority residing in low-income and middle-income countries. Globally, dementia entails significant economic burdens in 2019, amounting to a cost of 1.3 trillion US dollars. Informal caregivers devote considerable hours to providing care for those affected. Dementia imposes a greater caregiving and disability-adjusted life-year burden on women. A recent study has established a correlation between prolonged Proton Pump Inhibitor (PPI) usage and dementia, in addition to other neurodegenerative conditions. PPIs are frequently prescribed to treat peptic ulcers and GERD (gastroesophageal reflux disease) by decreasing stomach acid secretion. They alleviate acid-related symptoms through the inhibition of acid-secreting H+-K+ ATPase. In a number of observational studies, cognitive decline and dementia in the elderly have been linked to the use of PPIs. The precise mechanism underlying this relationship is unknown. These drugs might also alter the pH of brain cells, resulting in the accumulation of amyloid-beta (Aβ) peptides and the development of Alzheimer's disease (AD). Despite the compelling evidence supporting the association of PPIs with dementia, the results of studies remain inconsistent. The absence of a correlation between PPI use and cognitive decline in some studies emphasizes the need for additional research. Chronic PPI use can conceal underlying conditions, including cancer, celiac disease, vitamin B12 deficiency, and renal injury, highlighting dementia risk and the need for further investigations on cognitive health.

中文翻译:

质子泵抑制剂与认知健康:阐明痴呆症联系和共病风险的回顾

痴呆症是一个国际健康问题,其特征是认知能力下降导致日常功能受损,目前影响着全球超过 5500 万人,其中大多数居住在低收入和中等收入国家。在全球范围内,痴呆症在 2019 年带来了巨大的经济负担,损失达 1.3 万亿美元。非正式护理人员投入大量时间为受影响的人提供护理。痴呆症给女性带来了更大的护理和残疾调整生命年负担。最近的一项研究发现,除了其他神经退行性疾病之外,长期使用质子泵抑制剂 (PPI) 与痴呆症之间也存在相关性。 PPI 经常用于通过减少胃酸分泌来治疗消化性溃疡和 GERD(胃食管反流病)。它们通过抑制酸分泌 H+-K+ ATP 酶来缓解与酸相关的症状。在许多观察性研究中,老年人的认知能力下降和痴呆症与质子泵抑制剂的使用有关。这种关系背后的确切机制尚不清楚。这些药物还可能改变脑细胞的 pH 值,导致淀粉样β (Aβ) 肽的积累和阿尔茨海默病 (AD) 的发展。尽管有令人信服的证据支持 PPI 与痴呆症的关联,但研究结果仍然不一致。一些研究中质子泵抑制剂(PPI)的使用与认知能力下降之间缺乏相关性,这强调了进行额外研究的必要性。长期使用 PPI 可能会掩盖潜在的疾病,包括癌症、乳糜泻、维生素 B12 缺乏和肾损伤,这凸显了痴呆风险以及进一步研究认知健康的必要性。
更新日期:2024-02-28
down
wechat
bug